KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Liabilities and Shareholders Equity (2016 - 2025)

Acadia Pharmaceuticals has reported Liabilities and Shareholders Equity over the past 16 years, most recently at $1.6 billion for Q4 2025.

  • Quarterly results put Liabilities and Shareholders Equity at $1.6 billion for Q4 2025, up 31.69% from a year ago — trailing twelve months through Dec 2025 was $5.3 billion (up 33.53% YoY), and the annual figure for FY2025 was $1.6 billion, up 31.69%.
  • Liabilities and Shareholders Equity for Q4 2025 was $1.6 billion at Acadia Pharmaceuticals, up from $1.3 billion in the prior quarter.
  • Over the last five years, Liabilities and Shareholders Equity for ACAD hit a ceiling of $1.6 billion in Q4 2025 and a floor of $587.8 million in Q4 2022.
  • Median Liabilities and Shareholders Equity over the past 5 years was $736.7 million (2021), compared with a mean of $859.5 million.
  • Biggest five-year swings in Liabilities and Shareholders Equity: dropped 17.34% in 2022 and later soared 58.59% in 2024.
  • Acadia Pharmaceuticals' Liabilities and Shareholders Equity stood at $700.1 million in 2021, then dropped by 16.04% to $587.8 million in 2022, then increased by 27.41% to $749.0 million in 2023, then soared by 58.59% to $1.2 billion in 2024, then surged by 31.69% to $1.6 billion in 2025.
  • The last three reported values for Liabilities and Shareholders Equity were $1.6 billion (Q4 2025), $1.3 billion (Q3 2025), and $1.2 billion (Q2 2025) per Business Quant data.